GlassScriptPhysician profile
Timothy S Wolff
NPI 1649237587
$5,475.49
in general payments reported to CMS, 2019-2025
41 companies · $977 in 2025
The $977 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $1,087 · 2021: $896 · 2022: $612 · 2023: $852 · 2024: $441 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $922.83 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $663.91 | 2019-2025 | Qulipta, Ubrelvy, Linzess |
| Novo Nordisk INC | $460.81 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $376.99 | 2019-2023 | Otezla, Repatha |
| Eisai INC. | $305.01 | 2020-2021 | |
| Lilly USA, LLC | $304.71 | 2019-2025 | Mounjaro, Zepbound |
| Avita Medical Americas, LLC | $278.17 | 2023 | Recell |
| Pfizer INC. | $237.81 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.52 | 2021-2025 | |
| Allergan, INC. | $182.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $147.31 | 2020-2023 | Belsomra |
| Zyla Life Sciences, INC. | $147.25 | 2019 | |
| Jazz Pharmaceuticals INC. | $132.59 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $124.79 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $99.06 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wolff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.